Associated Papers
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA et al.
Blood Advances, 2023
37493986 (PubMed )
Supplement: BLOODA_ADV-2023-010779-mmc4.pdf
Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Fernández-Miranda I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
36269794 (PubMed )
Supplement: ccr-22-1654_supplementary_data_2_suppds2.xlsx › Table_S6__Mutational_data
de novo variant calling identifies cancer mutation signatures in the 1000 Genomes Project.
Ng JK et al.
Human Mutation, 2022
36054329 (PubMed )
Supplement: HUMU-43-1979-s002.xlsx › S14_IGLL5_DNVs
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J et al.
Frontiers in Immunology, 2022
35572515 (PubMed )
Supplement: Table_2.xlsx › S5
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Bruscaggin A et al.
Blood Advances, 2021
34500472 (PubMed )
Supplement: advancesADV2021004528-suppl2.xlsx › Table_S7
Select a paper to view details